Drug setback leaves Ascletis with an all-in bet on weight loss
The company’s two core hepatitis drugs were dropped from China’s state insurance scheme on July 1, effectively wiping out the remains of its legacy drug sales Key Takeaways: The company…
WuXi AppTec wages buyback campaign as U.S. pressure mounts
The drug services provider has been battling to shore up its share price and suffered a sharp sell-off after being added to a U.S. list of firms with suspected military…
Then there were two: BeOne moves beyond single-blockbuster dependence
The company’s Sonrotoclax is the first newly approved BCL-2 inhibitor in the U.S. in nearly a decade, giving BeOne a potential new hit beyond its Zanubrutinib blood cancer therapy Key…
Big deal, bigger doubts: CSPC slides after $18.5 billion pact
After months of rumors drove up its share price, the Chinese drug company has unveiled a record licensing deal with AstraZeneca, only to see its stock tumble Key Takeaways: Going…
Lagging in the weight-loss market? Take Fosun’s GLP-1 pill
Playing catch-up in the anti-obesity business, Pfizer has bought global rights to an oral weight-loss drug from Fosun Pharma in another big licensing deal Key Takeaways: With the drug still…
3SBio gears up for drugs battle with $400 million equity move
After grabbing the spotlight this year with a big licensing deal, the Chinese drug developer is now raising extra funds for R&D and shedding a non-core subsidiary Key takeaways: 3SBio…
Ming Yu seeks a share of the drug sector limelight
Led by a former research chief at drugs giant Hengrui, the Chinese biotech can boast solid credentials and big-name backers as it positions for a Hong Kong IPO Key Takeaways:…
Recent Articles
WuXi AppTec wages buyback campaign as U.S. pressure mounts
2359.HK
603259.SHG
Then there were two: BeOne moves beyond single-blockbuster dependence
6160.HK
688235.SHG
ONC.US
Lagging in the weight-loss market? Take Fosun’s GLP-1 pill
2196.HK
600196.SHG
RELATED ARTICLES
-
BRIEF: Ascletis raises $107 million to fund obesity drug trials
1672.HK - Precision-drug maker Impact Therapeutics ignites IPO frenzy
- Jacobio Pharma poised to turn a profit from precision cancer drugs
- A healthy return: drug spin-off nets Keymed up to $320 million
- Big deal, bigger doubts: CSPC slides after $18.5 billion pact
-
Drug spin-off trend gains traction with IPO by Hengrui offshoot
1276.HK600276.SHG
